Insilico Medicine was founded in 2014 and has developed state-of-the-art Artificial Intelligence platforms which allow for rapid identification of new molecular targets using multi-omics data and generation of novel compounds against targets by applying AI. Insilico established the HQ in Hong Kong and R&D offices in Taipei, Shanghai, and Europe. In 2020, Insilico Medicine was selected as the top 10 breakthrough technologies of the year. Later, Insilico announced a first-in-class preclinical candidate (PCC) targeting a novel target for Idiopathic Pulmonary Fibrosis (IPF) in 2021. The PCC nomination was completed every stage of drug discovery from target identification in only 18 months. With this amazing achievement, Insilico Medicine was recognized by known investors in biology and technology fields and received $255 million of round C for frontier research in the same year.